What's new? Log in Free sign up

Celcuity (CELC)

Company Profile

Company profile

Ticker

CELC

Exchange

Website

www.celcuity.com

CEO

Brian F. Sullivan

Incorporated

Location

Fiscal year end

Sector

Health Technology > Biotechnology

Industry (SIC)

Services - Medical Laboratories

Labcorp • Quest Diagnostics • Fortrea • GRAIL • Akumin • Oxford Square Capital • Burning Rock Biotech Limited • Exact Sciences • Caris Life Sciences • Guardant Health ...

Former names

Celcuity LLC

SEC CIK

Corporate docs

Articles of Incorporation & Bylaws

Underwriting Agreements

Plans of Reorganization

Material Contracts & Credit Agreements

Subsidiaries Lists

CELC stock data

1M 3M 6M 1Y

Analyst ratings and price targets

Last 3 months

Average target

$82.00

Low target

$66.00

High target

$110.00

HC Wainwright & Co.

Latest filings (excl ownership)

View all

Regulation FD Disclosure

$352.70 mm in debt / options / securities to be acquired, sold $130.00 mm, 2 investors

Celcuity Announces Upsized Senior Secured Term Loan Facility of $500 Million with Innovatus Capital Partners and Oxford Finance

Quarterly report

14 Aug 25

Celcuity Inc. Reports Second Quarter 2025 Financial Results and Provides Corporate Update

Entry into a Material Definitive Agreement

Celcuity Inc. Announces Pricing of Concurrent Public Offerings of

Prospectus supplement for primary offering

Prospectus supplement for primary offering

Free writing prospectus

Transcripts

View all

Earnings call transcript

Earnings call transcript

Earnings call transcript

Earnings call transcript

Earnings call transcript

Earnings call transcript

Earnings call transcript

Earnings call transcript

Earnings call transcript

Earnings call transcript

Latest ownership filings

View all

Brian F. Sullivan

Brian F. Sullivan

Beneficial ownership report

Beneficial ownership report (amended)

Financial summary

Financial statements Chart CELC financial data

Quarter (USD)	Jun 25	Mar 25	Dec 24	Sep 24
Revenue
Cost of revenue
Operating income
Operating margin
Net income
Net profit margin
Cash on hand
Change in cash
Diluted EPS

Annual (USD)	Dec 24	Dec 23	Dec 22	Dec 21
Revenue
Cost of revenue
Operating income
Operating margin
Net income
Net profit margin
Cash on hand
Change in cash
Diluted EPS

Cash burn rate (est.)	Burn method: Change in cash		Burn method: Operating income		Burn method: FCF (opex + capex)
	Last Q	Avg 4Q	Last Q	Avg 4Q	Last Q	Avg 4Q
Cash on hand (at last report)	46.35 mm	46.35 mm	46.35 mm	46.35 mm	46.35 mm	46.35 mm
Cash burn (monthly)	(no burn)	(no burn)	15.09 mm	12.41 mm	12.07 mm	10.03 mm
Cash used (since last report)	n/a	n/a	66.36 mm	54.60 mm	53.08 mm	44.12 mm
Cash remaining	n/a	n/a	-20.00 mm	-8.24 mm	-6.73 mm	2.23 mm
Runway (months of cash)	n/a	n/a	-1.3	-0.7	-0.6	0.2

Beta Read what these cash burn values mean

Financial data from Celcuity earnings reports.

Institutional ownership, Q4 2024

CELC institutional ownership history Ownership history

13F holders	Current	Prev Q	Change
Total holders	109	113	-3.5%
Opened positions	18	24	-25.0%
Closed positions	22	9	+144.4%
Increased positions	38	44	-13.6%
Reduced positions	29	17	+70.6%

13F shares	Current	Prev Q	Change
Total value	395.46 bn	435.16 bn	-9.1%
Total shares	45.68 mm	45.36 mm	+0.7%
Total puts	100.00	151.90 k	-99.9%
Total calls	17.50 k	30.80 k	-43.2%
Total put/call ratio	0.0	4.9	-99.9%

Largest owners	Shares	Value	Change
Soleus Private Equity Fund II	3.93 mm	$62.36 mm	0.0%
Soleus Capital Master Fund	3.87 mm	$45.38 mm	+47.6%
Biotechnology Value Fund L P	3.47 mm	$52.34 mm	0.0%
BVF	3.47 mm	$45.37 bn	0.0%
Baker Bros. Advisors	2.68 mm	$35.06 bn	+42.9%
Soleus Capital Management	2.57 mm	$33.58 bn	+106.0%
Perceptive Advisors	2.36 mm	$30.92 bn	0.0%
BlackRock	2.18 mm	$28.52 bn	+20.4%
Venrock Healthcare Capital Partners II	2.17 mm	$0.00	0.0%
Vanguard	1.65 mm	$21.62 bn	+1.5%

Largest transactions	Shares	Bought/sold	Change
Soleus Capital Management	2.57 mm	+1.32 mm	+106.0%
Ra Capital Management	0.00	-1.29 mm	EXIT
Soleus Capital Master Fund	3.87 mm	+1.25 mm	+47.6%
Commodore Capital	400.00 k	-1.12 mm	-73.7%
Baker Bros. Advisors	2.68 mm	+803.58 k	+42.9%
ExodusPoint Capital Management	0.00	-691.45 k	EXIT
JHG Janus Henderson	648.12 k	+648.12 k	NEW
Partner Fund Management	158.75 k	-551.51 k	-77.6%
MS Morgan Stanley	876.89 k	-515.81 k	-37.0%
BlackRock	2.18 mm	+368.62 k	+20.4%

Data from 13F filings, for the last complete 13F reporting period. For most recent data, click the ownership history button. Values as filed, not updated for current price. Long positions only.

Recent insider trades

CELC insider ownership history Insider history

Date	Owner	Security	Transaction	Code	Indirect	10b5-1	$Price	#Shares	$Value	#Remaining
11 Sep 25	Nigon Richard	Common Stock		Acquire X	No	No	7.5628	3,245	24.54 k	109,010
11 Sep 25	Nigon Richard	Common Stock		Acquire X	No	No	7.5628	4,672	35.33 k	105,765
11 Sep 25	Nigon Richard	Warrants Common Stock		Dispose X	No	No	7.5628	3,245	24.54 k	0
11 Sep 25	Nigon Richard	Warrants Common Stock		Dispose X	No	No	7.5628	4,672	35.33 k	0
8 Sep 25	Baker Bros. Advisors	Common Stock	Buy	Acquire P	Yes	No	58.0236	4,212	244.40 k	7,211,484
8 Sep 25	Baker Bros. Advisors	Common Stock	Buy	Acquire P	Yes	No	58.0236	388	22.51 k	704,308
8 Sep 25	Baker Bros. Advisors	Common Stock	Buy	Acquire P	Yes	No	56.22	151,524	8.52 mm	7,207,272
8 Sep 25	Baker Bros. Advisors	Common Stock	Buy	Acquire P	Yes	No	56.22	13,976	785.73 k	703,920
2 Sep 25	Sullivan Brian F.	Common Stock		Acquire X	No	No	8.05	104,340	839.94 k	1,370,199
2 Sep 25	Sullivan Brian F.	Warrants Common Stock		Dispose X	No	No	8.05	104,340	839.94 k	0

Data from 3, 4 and 5 filings. Values as filed, not updated for current price.

News

From Benzinga Pro

HC Wainwright & Co. Maintains Buy on Celcuity, Raises Price Target to $77

HC Wainwright & Co. analyst Swayampakula Ramakanth maintains Celcuity (NASDAQ:CELC) with a Buy and raises the price target from $66 to $77.

12 Health Care Stocks Moving In Monday's Intraday Session

WW International, Replimune Group, Datavault AI, GRAIL And Other Big Stocks Moving Higher On Monday

Dow Jumps Over 200 Points; Cleveland-Cliffs Shares Jump After Q3 Results

12 Health Care Stocks Moving In Monday's Pre-Market Session

Press releases

From Benzinga Pro

Celcuity Inc. Schedules Release of Third Quarter 2025 Financial Results and Webcast/Conference Call

MINNEAPOLIS, Nov. 05, 2025 (GLOBE NEWSWIRE) -- Celcuity Inc. (NASDAQ:CELC), a clinical-stage biotechnology company pursuing development of targeted therapies for oncology, today announced that it will release its

Celcuity To Present at Upcoming Stifel 2025 Healthcare Conference

MINNEAPOLIS, Nov. 04, 2025 (GLOBE NEWSWIRE) -- Celcuity Inc. (NASDAQ:CELC), a clinical-stage biotechnology company pursuing development of targeted therapies for oncology, today announced its participation in the

Celcuity Presents Updated Data at the 2025 ESMO Congress from Phase 1 Study Evaluating Gedatolisib Plus Darolutamide in Men with Metastatic Castration Resistant Prostate Cancer ("mCRPC")

Median radiographic progression free survival ("rPFS") was 9.1 months and the six-month rPFS rate was 67% No patients discontinued study treatment due to a treatment-related adverse event ("TRAE") MINNEAPOLIS, Oct. 18,

Celcuity Provides Update on Status of the PIK3CA Mutated Cohort of Phase 3 VIKTORIA-1 Trial and Releases Additional Data Analysis From Phase 1b Clinical Trial

Detailed Results from PIK3CA Wild-Type Cohort of Phase 3 VIKTORIA-1 Trial Presented at 2025 ESMO Congress Demonstrate Potential for Gedatolisib Regimens to be Practice Changing for Patients with HR+/HER2- Advanced Breast Cancer

We use cookies on this site to provide a more responsive and personalized service. Continuing to browse, clicking I Agree, or closing this banner indicates agreement. See our Cookie Policy for more information.